Market research
BJX1.F BioLife Solutions, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1B
- P/E ratio
- 34.88
- Analyst target
- 62.14
- Dividend yield
- Not available
- Beta
- 1.92
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- US09062W2044
- Market cap
- 1B
- P/E ratio
- 34.88
- Analyst target
- 62.14
- Dividend yield
- Not available
- Beta
- 1.92
About
About BioLife Solutions, Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BJX1.F discussion.
5 years, 5 months ago
BioLife Solutions, Inc is currently in a long term uptrend where the price is trading 33.3% above its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.5.
BioLife Solutions, Inc's total revenue rose by 77.5% to $15M since the same quarter in the previous year.
Its net income has increased by 82.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 156.4% to $-3M since the same quarter in the previous year.
Based on the above factors, BioLife Solutions, Inc gets an overall score of 4/5.